A fortified salt mixture includes sodium chloride salt grains and a multi-supplement food-additive admixed with the sodium chloride salt grains. The multi-supplement food additive includes particles, and each particle includes a core having a first supplement and a binder, a coating on the core, and a second supplement in the core and/or in the coating. A method for fortifying salt ncludes combining a first supplement, a second supplement, a binder and a coating to yield a multi-supplement food-additive; and admixing the multi-supplement food-additive with sodium chloride salt grains.

A fortified salt mixture includes sodium chloride salt grains and a multi-supplement food-additive admixed with the sodium chloride salt grains. The multi-supplement food additive includes particles, and each particle includes a core having a first supplement and a binder, a coating on the core, and a second supplement in the core and/or in the coating. A method for fortifying salt ncludes combining a first supplement, a second supplement, a binder and a coating to yield a multi-supplement food-additive; and admixing the multi-supplement food-additive with sodium chloride salt grains.

Disclosed are microcapsule compositions having a microcapsule that contains a microcapsule core and a microcapsule shell encapsulating the microcapsule core. The microcapsule has a particle size of 1 micron to 100 microns in diameter. The microcapsule core contains an active material. The microcapsule shell is formed of at least three moieties, in which a first moiety is derived from a polygalactomannan, a second moiety is derived from a polyisocyanate, and a third moiety is derived from a multi-functional aldehyde or a tannic acid.

The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (IId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can p be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP).

It relates to a food-grade coated particle comprising: a) a core that comprises a (C.sub.4-C.sub.12)polycarboxylic acid; and b) a coating that comprises: (i) an alkali metal salt of a (C.sub.4-C.sub.12)polycarboxylic acid wherein at least one carboxylic group of the (C.sub.4-C.sub.12)polycarboxylic acid is in the acid form, and at least one carboxylic group of the (C.sub.4-C.sub.12)polycarboxylic acid is in the salt form, and (ii) a film-forming agent; wherein the weight ratio between (i) and (ii) is from 20:80 to 40:60. It also relates to processes for the preparation of these food-grade coated particles, to their use as food additives, as well as to foodstuffs comprising them.

It relates to a food-grade coated particle comprising: a) a core that comprises a (C.sub.4-C.sub.12)polycarboxylic acid; and b) a coating that comprises: (i) an alkali metal salt of a (C.sub.4-C.sub.12)polycarboxylic acid wherein at least one carboxylic group of the (C.sub.4-C.sub.12)polycarboxylic acid is in the acid form, and at least one carboxylic group of the (C.sub.4-C.sub.12)polycarboxylic acid is in the salt form, and (ii) a film-forming agent; wherein the weight ratio between (i) and (ii) is from 20:80 to 40:60. It also relates to processes for the preparation of these food-grade coated particles, to their use as food additives, as well as to foodstuffs comprising them.

The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.

The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.

Disclosed is a lipid composition including, per 100% of its weight:—from 40% to 99.9% by weight of a component including, per 100% of its weight, from 90% to 100% by weight of beeswax and up to 10% by weight of at least one other lipid excipient,—from 0.1% to 60% by weight of at least one lipophilic surfactant.

Disclosed is a lipid composition including, per 100% of its weight:—from 40% to 99.9% by weight of a component including, per 100% of its weight, from 90% to 100% by weight of beeswax and up to 10% by weight of at least one other lipid excipient,—from 0.1% to 60% by weight of at least one lipophilic surfactant.